Verrica Pharmaceuticals Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-10.
Verrica Pharmaceuticals Inc. filed a Form D notice of an exempt securities offering with the SEC on December 10, 2025. The filing reports $50.02M sold. Its industry group is Pharmaceuticals. It names Jayson Rieger (Executive Officer, Director), John Kirby (Executive Officer), David Zawitz (Executive Officer) (SEC Form D, December 10, 2025).
Sell to companies like Verrica Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Verrica Pharmaceuticals Inc.
Free to see. No signup.
More on the people and the money behind Verrica Pharmaceuticals Inc., from the filings we hold.
TD Securities (USA) LLC received sales compensation on this raise and on 1 other raise we hold, nearest in date first:
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Verrica Pharmaceuticals Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Verrica Pharmaceuticals Inc. raises, hires or launches. No email unless you switch it on.
Watch Verrica Pharmaceuticals Inc. →Get the full cited report on Verrica Pharmaceuticals Inc.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Verrica Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Verrica Pharmaceuticals Inc. See pricing
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $50.02M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Jayson Rieger is named as Executive Officer and Director on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
John Kirby is named as Executive Officer on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
David Zawitz is named as Executive Officer on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
Noah Rosenberg is named as Executive Officer on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
Paul Manning is named as Director on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
Lawrence Eichenfield is named as Director on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
Diem Nguyen is named as Director on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
Mark Prygocki is named as Director on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
Sean Stalfort is named as Director on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
Gavin Corcoran is named as Director on the Form D that Verrica Pharmaceuticals Inc. filed with the SEC on 10 December 2025, one of 10 people that filing names.
10 people named on the filing — 4 holding an executive role and 6 as directors only.
Named as of the 2025-12-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Verrica Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Verrica Pharmaceuticals Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Verrica Pharmaceuticals Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Verrica Pharmaceuticals Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Verrica Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/verrica-pharmaceuticals-inc-form-d-25000001